search
Back to results

Biomarker Study of ATH434 in Participants With MSA

Primary Purpose

Multiple System Atrophy

Status
Not yet recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
ATH434
Sponsored by
Alterity Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple System Atrophy focused on measuring Multiple System Atrophy, ATH434, Neurodegenerative disease, Shy-Drager Syndrome, Movement disorders, Autonomic dysfunction, Synucleinopathies, Atypical parkinsonism, Biomarkers

Eligibility Criteria

30 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Participant has clinical features of parkinsonism. Participant has evidence of orthostatic hypotension and/or bladder dysfunction. Participant has ataxia and/or pyramidal signs on neurological examination. Participant has biomarker evidence of MSA in biologic fluid and on MRI. Exclusion Criteria: Participant is unable to swallow study drug. Participant is unable to attend study visits or complete study procedures. Participant has structural brain abnormality on MRI. Participant has any significant neurological disorder other than MSA. Participant has an unstable medical or psychiatric illness. Participant has a contraindication to, or is unable to tolerate, MRI or lumbar puncture.

Sites / Locations

  • Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ATH434

Arm Description

Outcomes

Primary Outcome Measures

Change in iron content as measured by brain MRI

Secondary Outcome Measures

Change in Aggregating alpha-Synuclein Levels
Change in Neurofilament Light Chain Levels
Change in Unified MSA Rating Scale (UMSARS) Score
Change in SF-36 Score

Full Information

First Posted
February 8, 2023
Last Updated
February 8, 2023
Sponsor
Alterity Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT05732415
Brief Title
Biomarker Study of ATH434 in Participants With MSA
Official Title
An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 1, 2023 (Anticipated)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
November 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alterity Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple System Atrophy
Keywords
Multiple System Atrophy, ATH434, Neurodegenerative disease, Shy-Drager Syndrome, Movement disorders, Autonomic dysfunction, Synucleinopathies, Atypical parkinsonism, Biomarkers

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ATH434
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
ATH434
Intervention Description
ATH434 taken BID
Primary Outcome Measure Information:
Title
Change in iron content as measured by brain MRI
Time Frame
Change from Baseline to Week 52
Secondary Outcome Measure Information:
Title
Change in Aggregating alpha-Synuclein Levels
Time Frame
Change from Baseline to Week 52
Title
Change in Neurofilament Light Chain Levels
Time Frame
Change from Baseline to Week 52
Title
Change in Unified MSA Rating Scale (UMSARS) Score
Time Frame
Change from Baseline to Week 52
Title
Change in SF-36 Score
Time Frame
Change from Baseline to Week 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participant has clinical features of parkinsonism. Participant has evidence of orthostatic hypotension and/or bladder dysfunction. Participant has ataxia and/or pyramidal signs on neurological examination. Participant has biomarker evidence of MSA in biologic fluid and on MRI. Exclusion Criteria: Participant is unable to swallow study drug. Participant is unable to attend study visits or complete study procedures. Participant has structural brain abnormality on MRI. Participant has any significant neurological disorder other than MSA. Participant has an unstable medical or psychiatric illness. Participant has a contraindication to, or is unable to tolerate, MRI or lumbar puncture.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alterity Clinical Trials
Phone
+1 650 300-2141
Email
ClinicalTrials@alteritytherapeutics.com
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessie Iregui
Email
jessica.iregui@vumc.org

12. IPD Sharing Statement

Learn more about this trial

Biomarker Study of ATH434 in Participants With MSA

We'll reach out to this number within 24 hrs